| Literature DB >> 32589755 |
Yi Zhao1, Jie Zhou1, Liuhua Pan2, Yujie Zhang1, Honggang Wang3, Wei Wu4, Jingsong He1, Jun Chen5, He Huang1.
Abstract
This study was designed to investigate the change of various indexes in patients with different types of coronavirus disease 2019 (COVID-19). Seventy-five patients with COVID-19 were collected from the First Affiliated Hospital, Zhejiang University School of Medicine, and they were classified into moderate, severe and critically severe types according to the disease severity. The basic information, blood routine, pneumonia-related blood indexes, immune-related indexes along with liver, kidney and myocardial indexes in patients with different types were analyzed. The analysis of immune-related indexes showed that the proportions of critically severe patients with abnormal interleukin-2 (IL-2) and IL-4 were higher than those of severe and moderate patients. In addition, the proportion of patients with abnormal total cholesterol increased as the severity of disease increased, and the proportion in critically severe patients was significantly higher than that in moderate patients. The patients with a more severe COVID-19 are older and more likely to have a history of hypertension. With the progression of COVID-19, the abnormal proportion of total white blood cell, neutrophils, lymphocytes, IL-2, IL-4, and total cholesterol increased. The change of these indexes in patients with different COVID-19 types could provide reference for the disease severity identification and diagnosis of COVID-19. In addition, the change in the total cholesterol level suggested that COVID-19 would induce some liver function damage in patients.Entities:
Keywords: clinical features; coronavirus; coronavirus disease 2019 (COVID-19); laboratory index; symptoms
Mesh:
Year: 2020 PMID: 32589755 PMCID: PMC7361356 DOI: 10.1002/jmv.26225
Source DB: PubMed Journal: J Med Virol ISSN: 0146-6615 Impact factor: 20.693
Comparison of clinical features of patients with different COVID‐19 types
| Moderate type | Severe type | Critically severe type |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Project Indicators | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | (Moderate vs severe) | (Moderate vs critically severe) | (Severe vs critically severe) |
| Age | 26 | 45.63 | 15.46 | 39 | 53.10 | 14.11 | 10 | 61.57 | 13.01 | .0487 | .0055 | .0951 | |||
| Sex | 26 | 12 | 14 | 0.5385 | 39 | 22 | 17 | 0.4359 | 10 | 7 | 3 | 0.3000 | .4564 | .2742 | .4959 |
| Hypertension | 26 | 23 | 3 | 0.1154 | 39 | 27 | 12 | 0.3077 | 10 | 4 | 6 | 0.6000 | .0821 | .0062 | .1407 |
| Diabetes | 26 | 26 | 0 | 0.0000 | 39 | 35 | 4 | 0.1026 | 10 | 9 | 1 | 0.1000 | / | / | 1.0000 |
| Temperature | 26 | 37.72 | 0.78 | 34 | 37.30 | 0.97 | 10 | 37.27 | 1.02 | .0885 | .1652 | .8943 | |||
Notes: Normal reference values: blood pressure (systolic pressure, 90‐139mm Hg; diastolic pressure, 60‐89mm Hg); fasting blood glucose (3.9‐6.1 mmol/L). Beyond or below the normal reference value is considered abnormal.
Abbreviation: COVID‐19, coronavirus disease 2019.
Comparison of blood routine and other pneumonia‐related blood indicators of patients with different COVID‐19 types
| Moderate type | Severe type | Critically severe type |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Project Indicators | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | (Moderate vs severe) | (Moderate vs critically severe) | (Severe vs critically severe) |
| Total Hb | 23 | 15 | 8 | 0.3478 | 34 | 19 | 15 | 0.4412 | 10 | 5 | 5 | 0.5000 | .5858 | .4611 | 1.0000 |
| Total WBC count | 26 | 18 | 8 | 0.3077 | 38 | 13 | 25 | 0.6579 | 10 | 5 | 5 | 0.5000 | .0103 | .4402 | .4682 |
| Neutrophil count | 26 | 17 | 9 | 0.3462 | 37 | 14 | 23 | 0.6216 | 10 | 2 | 8 | 0.8000 | .0420 | .0248 | .4568 |
| Lymphocyte count | 26 | 24 | 2 | 0.0770 | 38 | 18 | 20 | 0.5263 | 10 | 1 | 9 | 0.9000 | .0002 | <.0001 | .0654 |
| PCT | 23 | 13 | 10 | 0.4348 | 37 | 17 | 20 | 0.5405 | 10 | 4 | 6 | 0.6000 | .5959 | .4646 | 1.0000 |
| CRP | 15 | 4 | 11 | 0.7333 | 21 | 2 | 19 | 0.9048 | 6 | 1 | 5 | 0.8333 | .2100 | 1.0000 | .5453 |
Notes: Normal reference values: Total Hb, 131 to 172 g/L; total WBC, 4 to 10 × 109/L; neutrophil count, 2 to 7 × 109/L; lymphocyte count, 0.8 to 4.0 × 109/L; PCT, 0.00 to 0.05 ng/mL; CRP, 0.00‐8.00 mg/L. Beyond or below the normal reference value is considered abnormal.
Abbreviations: COVID‐19, coronavirus disease 2019; CRP, C‐reactive protein; Hb, hemoglobin; PCT, procalcitonin; WBC, white blood cell.
Comparison of immune‐related indicators of patients with different COVID‐19 types
| Moderate type | Severe type | Critically severe type |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Project Indicators | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | (Moderate | (Moderate | (Severe |
| TNF‐γ | 13 | 9 | 4 | 0.3077 | 17 | 12 | 5 | 0.2941 | 8 | 5 | 3 | 0.3750 | 1.0000 | 1.0000 | 1.0000 |
| IL‐10 | 18 | 5 | 13 | 0.7222 | 25 | 6 | 19 | 0.7600 | 10 | 2 | 8 | 0.8000 | 1.0000 | 1.0000 | 1.0000 |
| IL‐6 | 18 | 4 | 14 | 0.7778 | 24 | 4 | 20 | 0.8333 | 10 | 3 | 7 | 0.7000 | .7061 | .6744 | .3943 |
| IL‐2 | 18 | 17 | 1 | 0.0556 | 23 | 23 | 0 | 0.0000 | 8 | 0 | 8 | 1.0000 | / | / | / |
| IL‐4 | 18 | 17 | 1 | 0.0556 | 24 | 24 | 0 | 0.0000 | 8 | 0 | 8 | 1.0000 | / | / | / |
| IGM | 17 | 17 | 0 | 0.0000 | 29 | 28 | 1 | 0.0345 | 10 | 9 | 1 | 0.1000 | / | / | .4521 |
| IGA | 17 | 9 | 8 | 0.4706 | 29 | 27 | 2 | 0.0690 | 10 | 9 | 1 | 0.1000 | .0026 | .0912 | 1.0000 |
| IGG | 16 | 13 | 3 | 0.1875 | 29 | 22 | 7 | 0.2414 | 10 | 9 | 1 | 0.1000 | 1.0000 | 1.0000 | .6526 |
Notes: Normal reference values: TNF‐γ, 0‐20.06 pg/mL; IL‐10, 0 to 2.31 pg/mL; IL‐6, 0 to 6.61 pg/mL; IL‐2, 0 to 4.13 pg/mL; IL‐4, 0 to 8.37 pg/mL; LGM, 30 to 220 mg/dL; IGA, 100 to 420 mg/dL; LGG, 860 to 1740 mg/dL. Beyond or below the normal reference value is considered abnormal.
Abbreviations: COVID‐19, coronavirus disease 2019; IGA, Immunoglobulin A; IGG, Immunoglobulin G; IGM, Immunoglobulin M; IL, interleukin; TNF‐γ, tumor necrosis factor γ.
Comparison of liver, kidney, and myocardial indicators of patients with different COVID‐19 types
| Moderate type | Severe type | Critically severe type |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Project Indicators | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | Cases | Normal (mean) | Abnormal (SD) | Abnormal proportion | (Moderate vs severe) | (Moderate vs critically severe) | (Severe vs critically severe) |
| Total cholesterol | 22 | 16 | 6 | 0.2727 | 33 | 29 | 4 | 0.1212 | 8 | 6 | 2 | 0.2500 | 0.1747 | <0.0001 | 0.5777 |
| Albumin | 23 | 13 | 10 | 0.4348 | 37 | 13 | 24 | 0.6486 | 9 | 3 | 6 | 0.6667 | 0.1179 | 1.0000 | 1.0000 |
| Total bilirubin | 24 | 22 | 2 | 0.0833 | 38 | 38 | 0 | 0.0000 | 9 | 7 | 2 | 0.2222 | / | 0.2952 | / |
| Direct bilirubin | 24 | 21 | 3 | 0.1250 | 37 | 30 | 7 | 0.1892 | 9 | 7 | 2 | 0.2222 | 0.7261 | 0.5971 | 1.0000 |
| ALT | 23 | 21 | 2 | 0.0870 | 37 | 30 | 7 | 0.1892 | 9 | 7 | 2 | 0.2222 | 0.4604 | 0.5568 | 0.5568 |
| AST | 23 | 17 | 6 | 0.2609 | 37 | 26 | 11 | 0.2973 | 9 | 6 | 3 | 0.3333 | 1.0000 | 0.6853 | 1.0000 |
| Creatine kinase isoenzyme | 24 | 21 | 3 | 0.1250 | 34 | 32 | 2 | 0.0588 | 9 | 7 | 2 | 0.2222 | 0.6396 | 0.5971 | 0.1878 |
| CPK | 24 | 16 | 8 | 0.3333 | 34 | 23 | 11 | 0.3235 | 9 | 6 | 3 | 0.3333 | 1.0000 | 1.0000 | 1.0000 |
| GFR | 21 | 94.6 | 21.11 | 36 | 90.53 | 25.11 | 8 | 97.58 | 7.52 | 0.5356 | 0.7023 | 0.4402 | |||
Notes: Normal reference values: total cholesterol, 3.14 to 5.86 mmol/L; albumin, 40 to 55 g/L; total bilirubin, 0 to 26 μmol/L; direct bilirubin, 0 to 8 μmol/L; ALT, 9 to 50 U/L; AST, 15 to 40 U/L; creatine kinase isoenzyme, 2 to 25 U/L; CPK, 50 to 310 U/L. Beyond or below the normal reference value is considered abnormal.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; COVID‐19, coronavirus disease 2019; CPK, creatine phosphate kinase; GFR, glomerular filtration rate.